drugset / Trial / NCT01689753

Effect of the TEGO Connector in Preventing Tunneled Cuffed Hemodialysis Catheters From Dysfunction and/or Bacteremia

NCT01689753

Completed 66 enrolled Erasme University Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

The aim of the trial was to assess whether use of the TEGO connector was able to reduce the incidence of a composite endpoint of TCC-related dysfunction (TCC-D)or TCC-related bacteremia (TCC-B) in chronic hemodialysis (HD) patients carrying the TEGO® connector vs controls receiving trisodium citrate 46.7%.

Timeline

Start
2009-03
Primary completion
2010-04
Completion
2011-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator trisodium citrate Unknown 46.7 %

Indications

No indication recorded.